Altitude sickness: acclimatize safely and know when to descend

Quick answer

Altitude sickness happens when you gain elevation faster than your body can acclimatize to lower oxygen pressure. Acute mountain sickness (AMS) usually causes headache plus nausea, dizziness, or unusual fatigue after ascent. Stop going higher if symptoms appear. Descend and seek urgent help for confusion, loss of coordination, breathlessness at rest, a rapid drop in performance, or a worsening cough; these can signal high-altitude cerebral edema (HACE) or high-altitude pulmonary edema (HAPE).

The most reliable prevention is a conservative itinerary based on sleeping altitude, not fitness or willpower. Above 9,800 ft (3,000 m), the Wilderness Medical Society advises limiting the increase in sleeping elevation to no more than about 1,650 ft (500 m) per day and adding a rest day every three to four days. Medication can reduce risk in selected travelers, but it does not make an aggressive ascent safe and should be planned with a clinician.

Key facts

• Lower oxygen pressure triggers altitude illness when ascent outpaces acclimatization.
• Sleeping altitude determines risk more directly than the highest point reached on a day hike.
• Acute mountain sickness requires restraint: do not move to a higher sleeping elevation while symptoms continue.
• Ataxia or altered thinking signals HACE, a life-threatening emergency requiring descent and medical care.
• Breathlessness at rest or disproportionate effort signals HAPE, another emergency in which oxygen and descent take priority.

What is altitude sickness?

Air still contains about 21% oxygen at high altitude, but barometric pressure falls as elevation rises. Each breath therefore delivers fewer oxygen molecules to the lungs. Around 10,000 ft (3,050 m), inspired oxygen pressure is about 69% of the sea-level value, and arterial oxygen saturation commonly drops even in healthy travelers (CDC Yellow Book, 2026).

The body responds within minutes by breathing faster and increasing heart rate. Over the next three to five days, ventilation rises further, oxygenation improves, fluid balance changes, and cerebral blood flow adjusts. Red-blood-cell production matters over longer exposure, but it is not the main reason someone feels better during the first few days.

Altitude illness becomes a practical concern for unacclimatized people around 8,200 ft (2,500 m), although susceptible travelers can develop it lower. There is no single safe elevation for everyone. Risk depends on how high you sleep, how quickly you arrived, prior altitude history, individual susceptibility, exertion, and whether the itinerary allows recovery.

This is different from simply feeling slower on a climb. Maximal performance falls at altitude even after successful acclimatization. A fit runner may notice a higher effort at a familiar pace without being sick; a person with AMS feels unwell and has symptoms that affect function. The distinction matters because trying to “push through” illness can allow it to progress.

The three acute altitude illnesses

Altitude illness is not one uniform condition. The three main syndromes share hypoxia as a trigger but demand different levels of urgency.

Syndrome	Typical pattern	Field decision
Acute mountain sickness (AMS)	Headache plus nausea, dizziness, or fatigue after recent ascent	Stop ascent; observe closely; descend if worsening or not improving
High-altitude cerebral edema (HACE)	Loss of coordination, confusion, altered behavior, severe lassitude, or reduced consciousness	Medical emergency: descend, call for rescue, give oxygen if available
High-altitude pulmonary edema (HAPE)	Disproportionate breathlessness, rapid performance loss, cough, chest congestion, then breathlessness at rest	Medical emergency: oxygen and descent; do not leave the person alone

Acute mountain sickness: the warning stage

The 2018 Lake Louise consensus defines AMS for research around headache plus at least one additional symptom—gastrointestinal upset, fatigue or weakness, or dizziness—after altitude gain. Disturbed sleep was removed from the score because hypoxia itself can disrupt sleep without indicating AMS (Roach et al., 2018).

In the field, function is more useful than chasing a score. A person who feels ill or must reduce normal activity several hours to three days after ascending above roughly 8,200 ft (2,500 m) probably has AMS when another cause is not more likely. Mild symptoms can remain stable and resolve with time at the same elevation. Continuing upward while symptomatic is the dangerous choice.

HACE: altitude illness affecting the brain

HACE is an encephalopathy. Ataxia—an unsteady, poorly coordinated gait—is often its earliest objective sign. Confusion, unusual irritability, apathy, drowsiness, hallucinations, or inability to care for oneself may follow. A simple heel-to-toe walk can expose loss of coordination, but it is not a reason to delay evacuation.

Someone with suspected HACE may lack insight and insist they are fine. Treat altered behavior at altitude as a group safety problem, not a debate. The Wilderness Medical Society 2024 guideline recommends descent for suspected HACE in remote settings, plus oxygen and dexamethasone when available under an appropriate medical plan.

HAPE: altitude illness affecting the lungs

HAPE often begins with exercise breathlessness that is much worse than expected for the elevation or compared with companions. A sudden fall in walking pace, unusual weakness, dry cough, or a gurgling feeling in the chest can precede breathlessness at rest. Blue lips or skin and pink, frothy sputum are late signs; waiting for them is unsafe.

HAPE can occur with or without obvious AMS. A pulse oximeter may show hypoxemia out of proportion to the altitude, but symptoms and function should drive action. The WMS guideline identifies descent as the best treatment; supplemental oxygen is central when available. Small recreational oxygen cans contain too little oxygen for sustained treatment and must not delay evacuation.

How acclimatization lowers risk

Acclimatization is exposure plus time. The immediate goal is not to manufacture extra red blood cells overnight. It is to allow ventilation, acid-base balance, oxygen delivery, sleep, and exercise tolerance to adjust before adding another hypoxic load.

Sleeping elevation matters because hypoxemia is usually greatest during sleep. Hiking higher during the day and returning to a lower bed creates less sustained stress than moving camp to the day’s high point. This is the useful physiology behind “climb high, sleep low,” although the slogan does not justify extreme daytime gains or replace a conservative plan.

If that sleeping elevation will be in a tent, treat site hazards and insulation as a separate problem: our mountain tent camping guide explains how to screen terrain, weather, lightning exposure, and the complete sleep system.

Staging can help. In a randomized study, two days at moderate altitude before rapid exposure to 14,100 ft (4,300 m) reduced AMS compared with direct ascent, although protection varied by staging elevation (Beidleman et al., 2019). The result supports intermediate nights; it does not create one universal staging formula.

A practical sleeping-altitude plan

Use the itinerary as the primary prevention tool:

1. Avoid a large first-night jump when possible. The CDC notes that spending two or three nights around 8,000–9,000 ft (2,450–2,750 m) before going higher is markedly protective.
2. Above 9,800 ft (3,000 m), limit the daily sleeping gain. Keep it at or below about 1,650 ft (500 m) per day.
3. Add a rest day every three to four days. Also add one before or after an unavoidable large sleeping-elevation gain.
4. Do not ascend with symptoms. Remain at the same sleeping elevation for mild, stable AMS and observe closely.
5. Descend if the person worsens. Severe AMS, any HACE sign, or suspected HAPE requires a lower elevation and urgent care.

These are upper limits, not targets. A person with previous severe AMS, HACE, or HAPE may need a slower plan and specialist advice. Terrain, weather, group speed, rescue access, and the lowest safe descent route must be designed into the itinerary before departure.

If your trip involves steep racing or sustained climbing, the vertical running training guide can help with muscular and pacing preparation. It cannot acclimatize you to a sleeping altitude you have not experienced.

Winter athletes face the same physiology: our alpine skiing disciplines guide explains how speed, technical demand, fatigue, and altitude context differ from slalom through downhill.

Who is most likely to get altitude sickness?

The strongest practical predictors are:

• a rapid rise in sleeping elevation;
• a high first-night altitude;
• previous AMS, HACE, or HAPE under a similar ascent profile;
• limited acclimatization time;
• vigorous exertion soon after arrival;
• an itinerary that makes descent difficult.

Physical fitness does not prevent altitude sickness. Aerobic capacity may make the activity easier, but a high VO2 max does not remove the hypoxic exposure. Fitness can even encourage an aggressive pace that masks early fatigue until symptoms are harder to ignore.

If your goal is performance rather than ascent safety, use our altitude training guide for runners to plan the hypoxic dose, iron checks, pace changes, and return to sea level.

A problem-free previous trip is reassuring only when the elevation and ascent rate were similar. A faster itinerary or higher sleeping altitude changes the risk. Conversely, prior AMS does not guarantee illness on every future trip if the next ascent is slower.

Get medical advice before travel when risk is not routine

Talk with a clinician experienced in altitude or travel medicine before a rapid ascent, a remote itinerary, or travel with significant heart, lung, blood, neurologic, pregnancy, or sleep-related conditions. The CDC lists severe pulmonary hypertension, unstable angina, decompensated heart failure, severe poorly controlled lung disease, and recent heart attack or stroke among situations in which high-altitude travel may be contraindicated.

Sleep-disordered breathing deserves planning because oxygen levels commonly fall further overnight. Our sleep apnea guide explains why nocturnal hypoxemia matters, but decisions about CPAP, oxygen, or acetazolamide at altitude belong with a clinician who knows your condition and route.

Medication: useful tool, not permission to rush

Medication decisions are individual medical decisions. Kidney disease, pregnancy, allergies, drug interactions, prior HAPE, and the ascent profile can change what is appropriate. Do not borrow medication, begin a prescription during an emergency without a plan, or use this article as a dosing instruction.

Acetazolamide

Acetazolamide accelerates ventilatory acclimatization and reduces the incidence and severity of AMS. WMS recommends considering it for travelers at moderate or high risk, while gradual ascent remains the first priority. Trials support low-dose prophylaxis, and a 2025 phase III trial also found extended-release acetazolamide effective for prevention (Lipman et al., 2025).

Common effects include tingling, increased urination, and altered taste of carbonated drinks. Prior anaphylaxis to a sulfonamide or Stevens–Johnson syndrome is a contraindication in WMS guidance. A clinician should decide whether a supervised trial before a remote trip is appropriate.

Dexamethasone and HAPE-specific medication

Dexamethasone can prevent or rapidly improve AMS/HACE symptoms but does not create acclimatization; symptoms can return when it is stopped at altitude. It is generally reserved for specific high-risk or emergency plans and used alongside descent when severe illness occurs.

Nifedipine is primarily considered for people with known HAPE susceptibility. Other pulmonary vasodilators have narrow roles. None should be treated as routine hiking medication, and no drug replaces oxygen, descent, or evacuation when HAPE is suspected.

Ibuprofen has shown preventive benefit but was inferior to acetazolamide in a recent randomized comparison (Lipman et al., 2024). It also has gastrointestinal, kidney, bleeding, and cardiovascular considerations. “Available without prescription” does not mean “right for every traveler.”

Hydration, sleep, pulse oximetry, and common myths

Hydrate normally—do not force water

Dry air, faster breathing, and exercise can increase fluid needs. Dehydration can also mimic headache and fatigue. But forced overhydration has never been shown to prevent altitude illness and may cause dangerous hyponatremia. Drink to meet normal needs, monitor urine and thirst in context, and combine fluid with adequate food and electrolytes during prolonged exertion.

The hydration and healthy aging guide explains why both underhydration and excessive intake can distort symptoms and biomarkers. Water cannot compensate for an unsafe ascent rate.

Poor sleep alone is not AMS

Periodic breathing and repeated awakenings become common above about 9,000 ft (2,700 m). Sleep often improves with acclimatization. Because sleep disturbance is not specific to AMS, it was removed from the Lake Louise score. Headache plus illness and functional decline matters more.

Avoid using alcohol, opioids, or other respiratory depressants as sleep aids at altitude. Discuss sleep medication and existing sedatives with a clinician before travel.

A pulse oximeter is context, not clearance

Oxygen saturation normally falls with altitude, and normal ranges shift with elevation and time since arrival. Cold fingers, motion, nail products, poor circulation, device limitations, and skin pigmentation can affect readings. Our blood oxygen guide explains these measurement traps.

Use a consistent device on a warm, still hand and look for trends, but do not let one “good” number overrule confusion, ataxia, breathlessness at rest, or a rapid performance decline. Likewise, a low number without symptoms deserves a careful repeat and clinical context rather than panic. At high altitude, function and red-flag symptoms remain the decision anchors.

Use SuperAge as a preparation log, not an altitude diagnosis

SuperAge can help you review the health context around a trip: recent sleep, resting heart rate, HRV, respiratory trends, activity load, and recovery. That can reveal whether you arrived after poor sleep, illness, or accumulated fatigue—factors that may reduce your margin even though they do not diagnose AMS.

Create a simple trip log with sleeping elevation, symptoms, perceived exertion, route decisions, hydration, and any clinician-approved medication. Compare trends only within the same elevation and similar conditions. A wearable cannot rule out AMS, HACE, or HAPE, and an algorithm should never tell a symptomatic person to continue ascending.

Download SuperAge to keep recovery and health trends in one private view, while leaving altitude decisions to symptoms, the itinerary, your group, and medical guidance.

The altitude decision ladder

Use the safest matching row. Do not average a serious sign against several reassuring ones.

What you observe	What to do now
No symptoms, normal function	Continue only within the planned sleeping-altitude limit
Mild headache or nausea after ascent, normal coordination and breathing at rest	Stop ascent, rest at the same elevation, reassess frequently
Symptoms worsen or fail to improve at the same elevation	Descend; seek medical advice
Severe headache, repeated vomiting, marked weakness	Stop ascent and descend with support; evaluate for severe AMS/HACE
Unsteady heel-to-toe walk, confusion, unusual behavior, drowsiness	Treat as HACE: emergency descent, rescue, oxygen if available
Rapid performance loss, disproportionate breathlessness, cough, chest congestion	Suspect HAPE: stop exertion, oxygen and descent, urgent rescue
Breathlessness at rest, blue color, frothy sputum, inability to walk	Critical emergency: assisted evacuation; never leave the person alone

When descent is indicated, the WMS notes that symptoms often improve after losing 1,000–3,300 ft (300–1,000 m), but the needed drop varies. Descend until the person improves and reaches appropriate care. A person with HACE must not descend alone, and a person with HAPE should carry no load.

Portable hyperbaric chambers and supplemental oxygen can be lifesaving when descent is delayed, but they are bridges—not reasons to remain high. Group leaders should know who can authorize evacuation, how to contact rescue, which route loses altitude safely, and what weather could close that route.

Traveling with a dog adds a separate readiness and evacuation problem; human ascent limits cannot simply be assigned to the animal. Use the hiking-with-a-dog safety guide to plan veterinary clearance, conditioning, water, heat controls, paws, wildlife, and an assisted exit.

Pre-trip altitude checklist

Before booking:

• record the elevation of every overnight stop, not only summits;
• calculate each daily sleeping-elevation gain;
• identify rest days and lower alternatives;
• verify that the route permits descent in bad weather;
• disclose prior severe altitude illness and relevant medical conditions to a clinician;
• agree on group stop and evacuation rules.

Before ascending:

• start free of acute illness when possible;
• avoid a maximal workout immediately after arrival;
• carry enough food, normal hydration supplies, insulation, communication, and navigation;
• know which medications were prescribed to whom and why;
• practice using oxygen or a hyperbaric chamber if your team carries them;
• set a symptom check at breakfast, during movement, and before any higher sleep.

During the trip, pair every number with a question: Can the person walk steadily, think clearly, eat and drink, breathe comfortably at rest, and perform similarly to companions? A deteriorating answer is more important than summit timing.

Frequently asked questions

At what elevation does altitude sickness start?

Risk becomes meaningful for unacclimatized travelers around 8,200 ft (2,500 m), but susceptible people can develop AMS or HAPE around 6,600 ft (2,000 m). Use symptoms, sleeping altitude, ascent rate, and history together rather than treating one elevation as a guarantee.

How long does altitude acclimatization take?

The most important acute changes occur over roughly three to five days, while other adaptations continue for weeks. Every higher sleeping elevation creates a new exposure, so feeling well after several days at one altitude does not fully protect you after a large move upward.

Can I hike higher during the day and sleep lower?

Often yes. Daytime exposure with a return to a lower sleeping elevation can support acclimatization and is less stressful than sleeping at the day’s high point. Keep the day reasonable, avoid exhausting effort, and never hike higher to “force acclimatization” when symptoms are already present.

Does being very fit prevent altitude sickness?

No. Fitness improves movement capacity but does not eliminate susceptibility to AMS, HACE, or HAPE. Fit travelers still need a conservative ascent and may be at risk if their speed encourages a larger elevation gain.

Is headache always altitude sickness?

No. Dehydration, migraine, viral illness, carbon monoxide, exhaustion, hypoglycemia, hyponatremia, and other problems can look similar. Headache plus additional symptoms after ascent raises concern for AMS. At altitude, prioritize safety while considering other diagnoses.

Can a normal pulse oximeter reading rule out AMS?

No. AMS is a clinical syndrome, and oxygen saturation can be within the expected range for that altitude. Pulse oximetry is more useful for trends and for detecting hypoxemia that is disproportionate to elevation, especially when HAPE is suspected.

When can I ascend again after mild AMS?

Only after symptoms have fully resolved. WMS guidance says ongoing symptoms are a contraindication to further ascent or re-ascent. Resume conservatively and reconsider the itinerary, because the original ascent profile may have exceeded your acclimatization rate.

What symptoms mean I should descend immediately?

Loss of coordination, confusion, altered behavior, drowsiness, breathlessness at rest, rapid performance decline, worsening cough, blue lips or skin, or frothy sputum are emergency signs. Stop exertion, arrange descent and rescue, and use oxygen if available. Do not allow the person to go alone.

Key takeaways

• Altitude sickness reflects insufficient acclimatization to lower oxygen pressure, not weakness or poor motivation.
• Plan around sleeping elevation; above 9,800 ft (3,000 m), keep daily sleeping gain at or below about 1,650 ft (500 m) and add regular rest days.
• Never ascend while AMS symptoms continue.
• Ataxia or confusion suggests HACE; breathlessness at rest or rapid performance loss suggests HAPE.
• Descent is the decisive treatment for severe AMS, HACE, and HAPE; oxygen supports care but must not delay evacuation.
• Acetazolamide can reduce risk for selected travelers, but medication requires an individual plan and never validates a rushed itinerary.
• Fitness, forced hydration, supplements, and one wearable reading cannot guarantee safety.

References

1. Luks AM, Beidleman BA, Freer L, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update. Wilderness & Environmental Medicine. 2024;35(1S):2S–19S.
2. Hackett PH, Shlim DR. High-Altitude Travel and Altitude Illness. CDC Yellow Book 2026. Updated 2025.
3. UIAA Medical Commission. Emergency Field Management of Acute Mountain Sickness, HAPE and HACE. Consensus Statement No. 2. Updated 2024.
4. Roach RC, Hackett PH, Oelz O, et al. The 2018 Lake Louise Acute Mountain Sickness Score. High Altitude Medicine & Biology. 2018;19(1):4–6.
5. Luks AM, Hackett PH. Medical Conditions and High-Altitude Travel. New England Journal of Medicine. 2022;386:364–373.
6. Beidleman BA, Fulco CS, Staab JE, et al. Acute Mountain Sickness Is Reduced Following 2 Days of Staging During Subsequent Ascent to 4300 m. Medicine & Science in Sports & Exercise. 2019;51(2):329–338.
7. Lipman GS, Kanaan NC, Phillips C, et al. Efficacy and Safety of Extended-Release Acetazolamide Capsules for the Prevention of Acute Mountain Sickness. Randomized phase III trial. 2025.
8. Lipman GS, Phillips C, Saenz JS, et al. Ibuprofen Compared to Acetazolamide for the Prevention of Acute Mountain Sickness. Randomized placebo-controlled trial. 2024.